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Summary 
Accumulating genetic and biochemical evidences support a role for the SWI/SNF 
chromatin remodeling complex in cancer development and multiple core subunits of these 
complexes have been found to function as tumor suppressor genes. The core SWI/SNF 
subunit BAF57 mediates direct interactions with estrogen and androgen receptors (ER and 
AR) regulating their transcriptional activity. BAF57 gene maps to chromosome band 17q21 
in close proximity to the BRCA1 gene. This locus has been associated with frequent loss of 
heterozygosity (LOH) and allelic imbalance in breast cancers; however BRCA1 mutations 
are rare events in sporadic breast cancer with LOH in the region, suggesting that another 
tumor suppressor gene resides in this area. All these reasons prompted us to screen for 
mutations in the BAF57 gene using a panel of the most commonly used human breast 
cancer cell lines. All cell lines analyzed contain wild-type copies of BAF57 gene with the 
only exception of the breast ductal carcinoma cell line BT549. Sequencing of genomic 
DNA and cDNA generated from BT549 mRNA demonstrated the presence of a CA 
dinucleotide insertion in exon 5 of BAF57. The absence of wild-type BAF57 alleles 
indicates that this is a biallelic inactivating mutation that causes a frameshift and as a 
consequence a premature stop codon leading to a truncated BAF57 protein. A functional 
characterization of the truncated BAF57 showed that it has lost the ability to bind to ER but 
still binds to the nuclear receptor coactivator SRC1e. Furthermore, we observed that the 
expression of the truncated BAF57 increased the ability of SRC1e to potentiate 
transcriptional activation by ERα, suggesting that mutations in BAF57 could contribute to 
the oncogenic transformation in breast cancer cells. 
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Introduction 
Estrogens play a central role in mammary gland development and morphogenesis but 
they also are important in the proliferation and progression of breast cancer (reviewed in 
[1]). Although there is growing evidence that estrogens can act through nongenomic 
pathways most described estrogen actions are mediated by the estrogen receptor alpha 
(ERα) and beta (ERβ) acting as ligand-dependent transcription factors. Estrogen receptors 
belong to the nuclear receptor superfamily [2] and they regulate many physiological 
processes in response to its natural ligand, 17β-estradiol (E2). Endocrine therapy with ER 
antagonists, and specially tamoxifen, is the most effective systemic treatment for all stages 
of ER-positive breast cancer. However, many patients present primary resistance to 
endocrine therapy despite expressing high levels of ER and all patients with advance breast 
cancer eventually develop resistance to therapy ([3] and references therein). To understand 
the basis of the appearance of this resistance we need to elucidate the detailed molecular 
mechanisms that regulate ER activity. 
Upon ligand binding, ERs bind to specific DNA sequences (EREs) present in the 
promoters of estrogen-dependent genes, triggering the recruitment of the enzymatic 
activities responsible for the regulation of gene expression. To overcome the repressive 
environment that represents the tightly packed chromatin fiber, ERs recruit many chromatin 
remodeling enzymes that can be divided into two distinct classes; first, ATP-dependent 
chromatin remodeling complexes that use the energy of ATP hydrolysis to modify the 
location and association of nucleosomes with DNA, and second, enzymes that catalyze 
covalent posttranslational modifications in histones. These proteins are named collectively 
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nuclear receptor coregulators and they act in a concerted manner contributing to the 
reorganization of the chromatin templates and the recruitment of basal transcription factors 
and RNA polymerase II [4]. 
Several studies have demonstrated that mammalian SWI/SNF, an ATP-dependent 
chromatin remodeling complex, can enhance the transcriptional activity of the ER and 
several other nuclear receptors [5-10]. The SWI/SNF family comprises a number of large 
multiprotein complexes containing between eight to ten subunits. These complexes always 
contain a central catalytic subunit, BRM/SNFα or BRG1/SNFβ, and several other variable 
BRG1-associated factors (BAFs) that contribute to the enzymatic activity of the complex 
and facilitate the recruitment to specific transcription factors although the detailed functions 
of each individual subunit remain to be determined. Growing evidence indicates that 
SWI/SNF has a role in cancer development and several subunits either act as tumor 
suppressors or are required for the regulation of other tumor suppressor genes (Reviewed in 
[11, 12]). For instance, the SWI/SNF complex has been shown to associate with BRCA1 
through a direct interaction with BRG1/SNFβ subunit and mutations in BRG1/SNFβ 
abrogated stimulation of transcription by BRCA1 [13]. Mutations in the BRCA1 gene 
confer an increased risk for estrogen- and androgen-responsive cancers [14]. BRCA1 maps 
to chromosome band 17q21, a locus associated with frequent loss of heterozygosity (LOH) 
and allelic imbalance in breast cancers [15]. In sporadic breast cancer the BRCA1 gene is 
rarely mutated in samples with LOH in the locus [16], suggesting that other genes in this 
region might act as tumor suppressors. Interestingly, the gene that encodes BAF57, another 
SWI/SNF subunit, also maps to chromosome band 17q21. We have previously 
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demonstrated that BAF57 interacts directly with ER and also with all members of the p160 
family of nuclear receptor coactivators [10]. The interaction between BAF57 and ER is 
regulated by estrogen and BAF57 was shown to be essential for the coactivation of ER 
carried out by the p160 coactivators using a human breast ductal carcinoma cell line 
(BT549) reported to be negative for the BAF57 protein [17]. Moreover, BAF57 was 
recruited to estrogen-responsive promoters in a ligand-dependent manner, suggesting that 
the in vivo functions of ER as transcription factor might depend on the recruitment of 
SWI/SNF complexes by means of an interaction with BAF57. A previous report analyzed 
the BAF57 protein status in a number of human cell lines commonly used as in vitro 
models in breast cancer research [17]. In light of the new data reinforcing a role for BAF57 
in the control of ER activity, a key regulator of cell proliferation in estrogen-responsive 
tumors, we have extended those studies by sequencing the BAF57 gene in a panel of 
human breast cancer cell lines, looking for possible mutations that could have occurred 
during tumor progression and/or the establishment of the cell line that might affect normal 
ER-dependent signaling. Here we report our findings describing the first mutation 
characterized in the human BAF57 gene and discuss its possible implications in the 
development of breast cancer. 
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Materials and methods 
Cell culture 
Carcinoma-derived cells were grown as a monolayer on 75cm2 tissue culture flasks at 
37oC in a humid atmosphere maintained at 10% (v/v) CO2. Cells were maintained in either 
DMEM (ZR-75-1, MCF-7, T47D, MDA-MB-361, MDA-MB-231, PC-3) or RPMI 1640 
(BT549 and LNCaP) supplemented with 10% (v/v) fetal bovine serum. 
Plasmids 
The mutated BAF57 open reading frame found in BT549 cells was amplified by PCR 
and subcloned into pSG5 (pSG5-BT-BAF57) or pGEX-6P-1 (Amersham Pharmacia 
Biotech, GST-BT-BAF57). 
The following plasmids have been described previously: pMT2-MOR, pSG5-SRC1e, 
pGL3-2ERE-PS2-LUC, pSG5-ΔN-BAF57, GST-BAF57 [10]. 
Genomic Extraction 
The DNeasy tissue kit (Qiagen) was used for rapid isolation of total genomic DNA 
from cultured cells. Cells were grown to 50% confluency in a 9cm petri-dish (maximum 
number of cells 5×106), scraped off from the bottom of the petri dish, centrifuged at 1000 
rpm for 5 min and resuspended in 200µl PBS. Total genomic DNA was isolated according 
to the manufacturer’s protocol using two elution steps to yield DNA concentrations 
between 60-180 ng/µl. 
DNA sequencing 
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DNA was sequenced by a linear PCR method using dye-labelled terminators from 
Applied Biosystems. Typically, sequencing reactions were set-up consisting of 1µl DNA, 
8µl of Big Dye Terminator Ready Mix 3 (containing Taq polymerase and dye-labelled 
terminators) and 3µl (10ng/µl) of primer in a 20µl reaction. PCR reactions typically 
consisted of 25 thermo-cycles of: 94oC for 30 seconds, 50oC for 15 seconds and 60oC for 4 
minutes. Following the PCR, the DNA was precipitated, washed and then processed using 
the ABI 3100 capillary sequencer and the collection data using the ABI 3100 data 
collection software. 
Real-Time RT-PCR 
The Invitrogen ready-to-use TRIZOL reagent was used to isolate total RNA from 
cultured cells (>107). Precipitation and concentration of total RNA was achieved by the 
addition of isopropyl alcohol, centrifugation, and a subsequent 75% ethanol wash. Purified 
RNA was briefly air dried and re-dissolved in DEPC-treated water (Ambion). The RNA 
concentration and purity were determined by measurement of the OD260 and OD280 on a 
spectrophotometer. To obtain first strand cDNA, 2µg total RNA were treated with DNase I, 
and cDNA was prepared using the Superscript First-Strand synthesis System for RT-PCR 
according to the manufacturer’s instructions (Life Technologies, Inc.).  
Analysis of gene expression was performed by Real-time PCR using the ABI PRISM 
7700 Sequence detector following PE Applied Biosystems’ Taqman SYBR Green Master 
Mix protocol (Applied Biosystems, Foster City, CA). Reactions were carried out using 
specific primers for hBAF57 and the constitutively expressed L19 ribosomal coding gene 
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used as an internal control. BAF57 expression levels were normalized to L19 levels. Primer 
sequences may be obtained on request. 
GST pull-down assays 
Expression vectors for ERα or SRC1e-PAS were transcribed and translated in vitro 
with [35S]-methionine in reticulocyte lysate (Promega) according to the manufacturer’s 
protocol. GST fusion proteins of full-length BAF57 and truncated BT-BAF57 were 
induced, purified, bound to Sepharose beads (Amersham), and incubated with in vitro 
translated proteins (ERα or SRC1e-PAS) as described previously [10]. 
Transient transfections 
COS-1 cells were cultured in DMEM supplemented with 10% fetal bovine serum. 
Twenty-four hours before transfection, cells were plated in 24-well plates in phenol red-
free medium, supplemented with 5% dextran charcoal-stripped serum. Cells were 
transfected using a modified calcium phosphate protocol [18]. The transfected DNA 
included a pRL-CMV (Promega) control plasmid (5ng/well), the luciferase reporter 
plasmid pGL3-2XERE-PS2 (100 ng/well), pMT2-MOR (25 ng/well), pSG5-SRC1e (100 
ng/well), pSG5-ΔN-BAF57 (250 ng/well) or pSG5-BT-BAF57 (250 ng/well). Empty 
vectors were used to normalize the amounts of DNA. After incubation for 16 hours with the 
DNAs, the cells were washed and incubated in fresh medium in the presence of 10 nM 17β-
estradiol for 24 h. Subsequently, cells were harvested and extracts were assayed as 
described previously [18]. 
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RESULTS 
Screening cancer cell lines for mutations in the BAF57 gene 
In order to investigate the possibility that mutations in BAF57 occur in human breast 
cancer cell lines that might affect ER transcriptional activity, we have screened a panel of 
ER positive and ER negative breast cancer cell lines for mutations in the BAF57 gene that 
might affect estrogen signaling. In addition we also analyzed the sequence of BAF57 gene 
in two of the most commonly used human prostate cancer cell lines, LNCaP and PC-3 
(Table I). The BAF57 gene was sequenced directly from cDNA generated using RNA 
extracted from the cell lines MDA-MB-231, PC-3 and LNCaP and no mutations were 
found affecting BAF57 sequence. Genomic DNA was extracted from the other five cell 
lines studied and eleven sets of primers (forward and reverse) were used to both PCR-
amplify and sequence all eleven exons of BAF57. From all the cell lines sequenced, we 
found a CA dinucleotide insertion located in exon 5 of BAF57 derived from the BT549 
breast cancer cell line. The 5’-CA-3’ insertion was detected in two sequencing reactions 
with both primers from two independent PCR-amplification reactions of exon 5 (Figure 
1a). The presence of single peaks and no overlaps in the DNA sequencing suggests that the 
CA insertion is either a homozygous mutation or only one mutated allele is present.  
A restriction enzyme map analysis of BAF57 exon 5 showed that the CA mutation 
disrupted a unique Rsa I restriction endonuclease site (GT/AC).  Digestion of the wild-type 
sequence with this enzyme generates two fragments of approximately equal length (Figure 
1b). In order to confirm the presence of the CA mutation, exon 5 amplicons were PCR-
amplified using genomic DNA from BT549 and from MCF-7 (reference control with two 
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wild-type copies of BAF57 gene) and were digested with the Rsa I endonuclease. The sizes 
of the products obtained in the digestion reactions were analyzed by agarose gel 
electrophoresis (Figure 1c). Clearly, the presence of the CA mutation in the DNA derived 
from BT549 cells disrupted the Rsa I restriction site, resulting in the appearance of a single 
512-bp band in the gel corresponding to the undigested exon 5 amplicon, while DNA from 
MCF-7 only containing wild-type BAF57 copies gave rise to two fragments of 265 and 
247-bp that run as a single band in this 1.2% gel. The detection of only a single 512-bp 
band in the BT549-derived amplicon confirmed that BT549 do not have any wild-type 
BAF57 allele. 
Characterization of the novel BAF57 mutation found in BT549 cells 
We next investigated the consequences of the BT549 mutation at the protein level. 
Using the DNA Strider software we analyzed how the CA insertion at exon 5 affects the 
open reading frame (ORF) of BAF57 sequence and consequently the translation of the 
protein (Figure 2). The wild-type protein consists of 411 amino acids (Figure 2a), while as 
a result of the CA dinucleotide insertion a premature stop codon is introduced at nucleotide 
250 giving rise to a truncated protein that contains the first 75 amino acids of BAF57, 
followed by 9 random amino acids (Figure 2b). Furthermore this provides with an 
explanation to why in a previous study DeCristofaro et al. failed to detect full-length 
BAF57 protein in BT549 cells by Western blot analysis [17], since the mutation that we 
have identified in this breast cancer cell line generates a truncated BAF57 protein.  
In order to examine whether the breast ductal carcinoma cell line BT549 expressed the 
mutated BAF57 mRNA encoding the truncated protein, we isolated total RNA, generated 
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cDNA and mRNA levels were monitored by Real-Time RT-PCR (Figure 3). The relative 
expression levels of BAF57 were analyzed in a number of breast and prostate carcinoma-
derived cell lines (BT549, ZR-75-1, MCF-7, T47D, LNCaP and PC-3) and we found 
detectable BAF57 mRNA expression in BT549 cells. However, it is noteworthy that BT549 
cells express significantly lower BAF57 mRNA levels compared to the rest of cell lines 
examined. The presence of the CA mutation was also confirmed by sequencing the cDNA 
generated from BT549 cells (data not shown). 
In an attempt to characterize the functional effects of the BT549-derived BAF57 (BT-
BAF57) truncated protein, we subcloned the mutated ORF into the bacterial expression 
vector pGEX-6P1 and the mammalian expression vector pSG5, to be used in GST pull-
down assays and transient transfection experiments respectively. 
We have previously demonstrated that BAF57 directly interacts with both ERα and 
p160 coactivators and this association is required for the ability of p160 coactivators to 
potentiate ER-mediated transcription in transient transfection systems [10]. The CA 
insertion leads to a truncated BAF57 protein what could have important consequences on 
the functionality of this protein. We carried out GST pull-down assays to investigate the 
ability of the truncated BT-BAF57 protein to interact in vitro with both ERα and the p160 
coactivator SRC1e, as compared to wild-type full-length BAF57. In a set of GST pull-down 
experiments in vitro translated 35S-labelled ERα was incubated with GST-BAF57 (wild-
type full-length BAF57) or GST-BT-BAF57 (truncated BAF57) fusion proteins (Figure 
4a). According to our previous data, we observed that ERα directly binds to GST-BAF57 
in a ligand-dependent manner with a strong interaction detected in the presence of estrogen 
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(E2) (Figure 4a). However, the in vitro binding of ERα to GST-BT-BAF57 was 
dramatically impaired (Figure 4a). No interaction was observed in the presence of GST 
alone, as a proof of the specificity of BAF57-ERα interaccion. In another set of 
experiments we analyzed the in vitro interaction between the bHLH-PAS domain (amino 
acids 1-361) of SRC1e (responsible for mediating the interaction with BAF57) and GST-
BAF57 or GST-BT-BAF57 fusion proteins (Figure 4b). In vitro translated 35S-labelled 
PAS-SRC1e interacted in the same weak but specific manner with both full-length BAF57 
and BT-BAF57. Collectively the data from the in vitro pull-down assays indicate that 
although the BT-BAF57 still retains its ability to interact with p160 coactivators similar to 
that of full-length BAF57, this truncated protein lacks capability of binding ERα. 
Next we investigated the possible functional consequences of the expression of the 
truncated BAF57 protein in ERα transcriptional activity. We and others have demonstrated 
that several truncated BAF57 proteins act as dominant-negative forms on steroid receptor 
dependent transcriptional activity when expressed in cells containing endogenous BAF57 
[10, 20]. To test whether the truncated BT-BAF57 was able to modulate the transcriptional 
activity of ERα we examined transcription from the 2ERE-PS2-LUC reporter in the 
presence of the ERα, SRC1e and either the previously characterized dominant negative 
ΔN-BAF57 or the truncated BT-BAF57 cloned from BT549 cells. As previously reported 
ΔN-BAF57 dramatically inhibited the ability of SRC1e to potentiate transcriptional activity 
of ERα (Figure 4c). Surprisingly, the expression of BT-BAF57 did not reduce SRC1e 
coactivation potential; on the contrary, we observed an increase in the SRC1e coactivation 
of ERα in the presence of BT-BAF57 (Figure 4c). 
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Discussion 
The considerable genetic and biochemical evidence linking BAF57 to cancer prompted 
us to screen a number of breast and prostate cancer cell lines for mutations in the BAF57 
gene. The human BAF57 gene maps to chromosome band 17q21, in close proximity to the 
BRCA1 gene, a locus associated with frequent LOH and allelic imbalance in breast, ovarian 
and prostate cancer and it has previously been suggested that BAF57, based on its 
involvement in DNA transcription and repair events, could function as a tumor suppressor 
[17]. Moreover the involvement of BAF57 in the regulation of transcriptional activity by 
ERα [10], which is a key regulator of cell proliferation in normal as well as in cancerous 
breast and ovarian tissues, further reinforces this notion. In this study we address the 
characterization of BAF57 gene in the most widely used human cancer cell lines exploited 
as in vitro models in breast cancer research [21]. The experimental approach chosen was 
preferentially sequencing genomic DNA, because this allows us to detect mutations in 
BAF57 even in cases where expression of the gene could be lost during cancer development 
or cell line establishment. Five out of six breast cancer cell lines studied do not contain 
mutations in BAF57 affecting the expressed protein or the DNA sequence. However, a CA 
dinucleotide insertion in BAF57 was found in the BT549 breast cancer cell line. The 
observation of single peaks and no overlaps in the electropherogram in the DNA sequence 
suggests that the wild-type BAF57 allele is not present in BT549 cells. A restriction 
digestion analysis of BAF57 exon 5 further confirmed that these cells only contain mutated 
copies of BAF57. Therefore, either the CA insertion occurs in homozygosis or, more likely, 
according to the Knudson’s two-hit model [22], the acquisition of this mutation in one copy 
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of BAF57 was followed by the subsequent loss of the remaining wild-type copy of the 
gene. Although we do not have conclusive evidence several observations support this 
notion. During the PCR-amplification reactions we observed that for BT549 almost double 
the amount of genomic DNA was required, relative to that of other cell lines, in order to 
generate the same amount of amplified product. In addition, the results of the Real-Time 
RT-PCR, where it was shown that BT549 cells express significantly lower levels of BAF57 
mRNA than the other cell lines further suggest the presence of a single BAF57 allele in this 
cell line, although we cannot rule out the possibility that other mechanisms, like promoter 
methylation, could also be responsible for this low expression. As mentioned above, BAF57 
maps to a chromosome area that has been associated with LOH in breast cancer and our 
data suggest that this is the case in BT549 cells. The CA insertion located in BAF57 exon 5 
causes a frameshift in the ORF and introduces a premature stop codon, leading to a 
truncated protein (BT-BAF57) consisting of eighty-five amino acids, of which only the first 
seventy-five correspond to wild-type BAF57 protein. 
 In view of the critical role of BAF57, acting through SWI/SNF complexes, in the 
regulation of gene transcription mediated by ERα and AR, the confirmation that all other 
breast and prostate cancer cell lines analyzed express wild-type BAF57 might be relevant in 
future studies performed using those cellular models addressing the molecular mechanisms 
of action of SWI/SNF complexes, ER or AR. 
BT549 is a breast-ductal carcinoma cell line that does not express ER and has a 
truncated retinoblastoma (pRB) transcript ([23] and references therein). A previous study 
had also shown that the BAF57 protein was undetectable by Western blotting in this cell 
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line [17] and the mutation we identified in the BAF57 gene that results in the generation of 
a truncated protein explains why. We have also shown that BT549 cells express BAF57 
mRNA encoding the truncated protein. BT-BAF57 does not interact with ER but it is still 
able to bind in vitro to the SRC1e coactivator in the same manner as the full-length wild-
type protein raising the possibility that the truncated protein may interfere not only with 
ERα regulation, but also with a number of other nuclear receptor-dependent gene 
regulation pathways. Alterations on AR transcriptional activity might also be relevant in the 
generation of the transformed phenotype in breast cancer cells because its activity requires 
both functional p160 coactivators and BAF57, and AR can mediate testoterone 
antiproliferative and proapoptotic effects in mouse breast cancer models (reviewed in [24]) 
In most cases cancer arises after an accumulation of mutations that may affect different 
cell proliferation-regulatory pathways. In the case of BT549, at least three mutations are 
present, each potentially linked to generation of breast cancer. The pRB protein is a major 
tumor suppressor and transfection studies have shown that the SWI/SNF complex 
associates with pRB to inhibit cell proliferation [25]. BT549 cells are also ER negative and 
estrogen is a major regulator of cell proliferation in normal as well as in breast cancer 
tissues. Finally, BAF57 is a core subunit of all human SWI/SNF complexes and a truncated 
BAF57 protein may potentially interfere with both pRB-mediated and ERα-mediated 
pathways. We have observed that expression of BT-BAF57, in contrast to the reported 
dominant-negative action of other artificial BAF57 deletion mutants, is able to increase the 
ability of SRC1e to potentiate transcriptional activation by ERα. Therefore, if this mutation 
occurred prior to the loss of ER expression, it could have contributed to the aberrant 
 17 
cellular proliferation through excessive estrogen-dependent signaling. It is also possible 
that the BAF57 mutation occurred first and pleiotropic effects mediated by deficient 
SWI/SNF complexes led to the generation of additional mutations. BAF57, acting through 
SWI/SNF complexes, participates in the regulation of gene expression carried out by many 
types of transcription factors other than ER and AR. A recent study has shown that stably 
expression of full-length wild-type BAF57 in BT549 cells reduced the transformed 
characteristics of this breast cancer cell line, inducing cell cycle arrest and apoptosis and 
restoring contact inhibition [26], strongly supporting a role for BAF57 as tumor suppressor. 
To address the possible contribution of this mutation in BAF57 to aberrant ER-dependent 
signaling it will be necessary to stably express BT-BAF57 mutant in cell lines expressing 
both wild-type BAF57 and ER in order to analyze how BT-BAF57 affects estrogen 
dependent gene expression and cell proliferation. 
The finding of a mutation in BAF57 in one breast cancer cell line out of just six that 
were screened strengthens our view that BAF57 may be associated with tumor generation 
in the mammary gland and it suggests that it will be worthwhile to initiate studies to screen 
primary human breast cancer samples for potential mutations in the BAF57 gene.  
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 Figure legends 
 
Figure 1. Identification of a CA dinucleotide insertion in exon 5 of the BAF57 gene 
in the human BT549 breast cancer cell line. (a) The mutation was detected in two 
independent sequencing reactions using both the forward (F) and the reverse (R) primers. 
The wild-type (WT) sequence of exon 5 is given in the bottom line. The data from the 
sequencing reactions were processed by using the Seqman software (Macintosh). (b) 
Schematic representation of the restriction digestion strategy used. The Rsa I restriction site 
(GTAC) is located in the middle part of BAF57 exon 5. Digestion of the PCR-amplified 
wild-type exon 5 amplicon generates two DNA fragments of similar size (~250bp), while in 
the BT549-derived amplicon the CA insertion disrupts the Rsa I restriction site and the 
original fragment remains undigested (~500bp). (c) Restriction digestion analysis of 
BAF57 exon 5 with Rsa I. The restriction digestion reactions were terminated by addition 
of DNA loading buffer and the sizes of the digestion products were analyzed by agarose gel 
(1.2%) electrophoresis. Two independently generated PCR amplicons were analyzed in 
each case. 
Figure 2. The CA insertion present in BT549 cells generates a truncated BAF57 
protein. (a) Wild-type BAF57 open reading frame. The wild-type human BAF57 protein 
consists of 411 amino acids. (b) The CA insertion identified in BT549 cells (indicated in 
capital letters) causes a frameshift leading to a premature stop codon at position 85 
(indicated by an asterisk) which generates a truncated BAF57 protein consisting of the first 
75 residues of BAF57 protein followed by 9 random amino acids (highlighted inside a 
rectangle). 
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Figure 3. Comparison of the relative BAF57 expression levels in a panel of breast 
and prostate cancer cell lines by Real-Time RT-PCR. Total RNA was extracted from a 
number of breast and prostate cancer cell lines (BT549, ZR-75-1, MCF-7, T47D, LNCaP 
and PC-3). cDNA was generated and BAF57 mRNA expression analysed by Real-Time 
RT-PCR using L19 as control gene. The values are expressed relative to the BAF57 mRNA 
levels in BT549 cells assigned as 1. 
Figure 4. Functional characterization of the BT-BAF57 truncated mutant. (a) In 
vitro interaction of BAF57 and BT-BAF57 with ERα. Binding of GST fusion proteins of 
wild type BAF57 (GST-BAF57) or truncated BT-BAF57 (GST-BT-BAF57) to 35S-labelled 
ERα in the presence of 100nM 17β-estradiol (E2) or vehicle (-). (b) In vitro interaction of 
BAF57 and BT-BAF57 with SRC1e. Binding of GST fusion proteins of wild type BAF57 
(GST-BAF57) or BT-BAF57 (GST-BT-BAF57) to 35S-labelled SRC1 bHLH-PAS domain 
(amino acids 1-361). In each panel, the input lane represents 10% of the total volume of 
lysate used in each reaction. (c) Effect of BT-BAF57 expression on transcriptional 
activation by ERα in cells expressing endogenous BAF57. COS-1 cells were transiently 
transfected with expression vectors for ERα and SRC1e, the 2XERE-pS2 luciferase vector, 
the dominant negative ΔN-BAF57 or BT-BAF57. In each case, after transfection, cells 
were washed and incubated with vehicle (white bars) or 17β-estradiol (back bars) at 10-8 for 
24 h. Subsequently, cell lysates were assayed using a dual luciferase reporter system. 
Normalized values are expressed relative to the activity of ERα alone in the presence of 
ligand. The results shown represent the average of two independent experiments assayed in 
duplicate. 
Table 1. Summary of human cancer cell lines screened 
Breast cancer cell lines Genomic DNA cDNA ER status BAF57 mutations 
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MCF-7 + - + - 
ZR-75-1 + - + - 
BT549 + + - + 
T47D + - + - 
MDA-MB-361 + - + - 
MDA-MB-231 - + - - 
Prostate cancer cell lines     
PC-3 - + +/- - 
LNCaP - + +/- - 
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